KAT2A and cholangiocarcinoma: Given that PARP1 inhibitors have already received FDA approval for treating DNA damage repair-deficient tumors, this study further establishes a solid experimental and theoretical foundation for extending the application of USP1 inhibitors, GCN5 inhibitors, or PARP1 inhibitors to cholangiocarcinoma, potentially paving the way for new combination targeted therapies.